Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun 3;26(6):euae161.
doi: 10.1093/europace/euae161.

Incidence, implications, and management of sense-B-noise failure in subcutaneous cardioverter-defibrillator patients: insights from a large multicentre registry

Affiliations
Multicenter Study

Incidence, implications, and management of sense-B-noise failure in subcutaneous cardioverter-defibrillator patients: insights from a large multicentre registry

Jonas Wörmann et al. Europace. .

Abstract

Aims: Subcutaneous implantable cardioverter-defibrillators (S-ICDs) offer potentially distinct advantages over transvenous defibrillator systems. Recent randomized trials showed significantly lower lead failure rates than transvenous ICD. Still, S-ICDs remain associated with the risk of inappropriate shocks (IAS). While previous studies have reported varying causes of IAS, this study explores a rare cause of IAS, referred to as 'sense-B-noise.' It was recently described in case series, but its incidence has not been studied in a large cohort of S-ICD patients.

Methods and results: We retrospectively reviewed data from patients implanted with S-ICD models 1010, A209, and A219 between October 2009 and July 2023 across nine centres in Europe and the USA. The analysis concentrated on determining the incidence and understanding the implications of sense-B-noise events. Sense-B-noise represents a rare manifestation of distinct electrogram abnormalities within the primary and alternate sensing vectors. Data were collected from medical records, device telemetry, and manufacturer reports for investigation. This registry is registered on clinicaltrials.gov (NCT05713708). Subcutaneous implantable cardioverter-defibrillator devices of the 1158 patients were analysed. The median follow-up time for all patients was 46 (IQR 23-64) months. In 107 patients (9.2%) ≥1 IAS was observed during follow-up. Sense-B-noise failure was diagnosed in six (0.5 and 5.6% of all IAS) patients, in all patients, the diagnosis was made after an IAS episode. Median lead dwell time in the affected patients was 23 (2-70) months. To resolve the sense-B-noise defect, in three patients reprogramming to the secondary vector was undertaken, and two patients underwent system removal with subsequent S-ICD reimplantation due to low amplitude in the secondary vector. In one patient, the secondary vector was initially programmed, and subsequently, an S-ICD system exchange was performed due to T-wave-oversensing IAS episodes.

Conclusion: This multicentre analysis' findings shed light on a rare but clinically highly significant adverse event in S-ICD therapy. To our knowledge, we provide the first systematic multicentre analysis investigating the incidence of sense-B-noise. Due to being difficult to diagnose and limited options for resolution, management of sense-B-noise is challenging. Complete system exchange may be the only option for some patients. Educating healthcare providers involved in S-ICD patient care is crucial for ensuring accurate diagnosis and effective management of sense-B-noise issues.

Keywords: Device malfunction; Inappropriate shocks; Multicentre registry; Sense-B-noise; Subcutaneous implantable cardioverter-defibrillator (S-ICD).

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.W. reports having received lecture fees from Abbott and Boston Scientific and educational fees from Boston Scientific and Johnson&Johnson. J.L. and D.S. report having received lecture fees from Johnson&Johnson, Abbott, and Boston Scientific. A.S. reports having received lecture fees from Medtronic, Boston Scientific, Abbott, and Johnson&Johnson. J.H. reports having received educational fees from Boston Scientific, Medtronic, Abbott, and Biotronik and speaker fees from Abbott. N.S. reports having received research funding from Abbott. N.B. reports having received an educational grant from Biotronik and speaker fees from Medtronic and Abbott, all outside this submitted work. A.B. reports having received consultant and/or speaker fees from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Bristol-Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, Pfizer, and Spectranetics/Philips. J.S. reports having received educational fees from Boston Scientific and Johnson&Johnson and lecture fees from Abbott. All other authors report nothing to declare.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Electrogram showing IAS due to sense-B-noise during sensing of the alternate vector. Featuring the distinct findings of sense-B-noise: (1) saturated signal, (2) diminished QRS amplitude, (3) noise, and (4) high-voltage therapy with cessation of noise followed by ‘normal’ QRS-complexes. IAS, inappropriate shock.

Similar articles

References

    1. Knops RE, Pepplinkhuizen S, Delnoy PPHM, Boersma LVA, Kuschyk J, El-Chami MFet al. . Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J 2022;43:4872–83. - PMC - PubMed
    1. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J, El-Chami MFet al. . Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383:526–36. - PubMed
    1. Gold MR, Lambiase PD, El-Chami MF, Knops RE, Aasbo JD, Bongiorni MGet al. . Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial. Circulation 2021;143:7–17. - PMC - PubMed
    1. Viani S, Migliore F, Ottaviano L, Biffi M, Ammendola E, Ricciardi Get al. . Longevity of model 3501 subcutaneous implantable cardioverter-defibrillator leads in clinical practice. Hear Rhythm 2022;19:1206–7. - PubMed
    1. Gold MR, El-Chami MF, Burke MC, Upadhyay GA, Niebauer MJ, Prutkin JMet al. . Postapproval study of a subcutaneous implantable cardioverter-defibrillator system. J Am Coll Cardiol 2023;82:383–97. - PubMed

Publication types

Associated data